HOME >> MEDICINE >> NEWS
Positive study results for methylphenidate transdermal system

Philadelphia, US October 24, 2005 Shire announced at a major medical meeting in Toronto, Canada, that its investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) and was generally well tolerated in patients aged 6 to 12 in two clinical trials.

"Children with ADHD must cope with symptoms throughout the day and in a variety of environments, such as in the classroom, during after-school activities, or while at home," explained Sharon Wigal, Ph.D., associate clinical professor of Pediatrics at the University of California, Irvine Child Development Center. "While oral methylphenidate has long been a first-line treatment for patients with ADHD symptoms, if approved, this transdermal patch formulation would provide health care professionals and parents the first and only non-oral medication for children with the disorder."

The MTS patch was developed by Noven Pharmaceuticals, Inc. and combines the active ingredient of methylphenidate with Noven's patented DOT Matrix transdermal technology. This transdermal delivery system was designed to provide continuous medication release throughout the day. The transdermal system releases medication that passes through the skin and directly into the blood stream. The patch is water-resistant.

Data from phase II and phase III clinical trials presented Thursday and Friday in Toronto demonstrated statistically significant improvements in the primary and secondary endpoints analyzed for children treated with MTS compared to children treated with placebo.

The phase II analog classroom study included 79 children with ADHD. The patch was worn for nine hours, and efficacy was assessed throughout the day for twelve hours. MTS demonstrated statistically significant improvement over placebo on the measures tested. Behavior, which was measured using the Swanson, Kotkin, Agler, M-Flynn,
'"/>

Contact: Matthew Cabrey
1-484-595-8248
Porter Novelli
24-Oct-2005


Page: 1 2

Related medicine news :

1. Positive results more likely from industry-funded breast cancer trials
2. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
3. Positive parenting helps encourage healthy sun habits in children
4. Positive results for ACRUXs lead product in US Phase 3 trial
5. Positive outcome of Medicare drug benefit
6. Positive study results for methylphenidate transdermal system
7. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
8. Penn study finds pro-death proteins required to regulate healthy immune function
9. New study shows promise in reducing surgical risks associated with surgical bleeding
10. New study counts the economic cost of persistent pain in Australia
11. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2019)... ... April 18, 2019 , ... Dr. Matt Nejad is a ... full menu of cosmetic and general dental care services. Dr. Nejad is most ... relies on minimally-invasive techniques in restorative dentistry. Biomimetic dentistry uses a more holistic ...
(Date:4/17/2019)... GULF BREEZE, Fla. (PRWEB) , ... April 17, 2019 , ... ... in the headlines, scientists are working to curb the death toll by looking for ... Society Spring 2019 National Meeting & Exposition this week. , Naloxone (often known ...
(Date:4/17/2019)... ... April 17, 2019 , ... Purple Biosciences today ... California-made supplement was designed to lessen the negative effects of alcohol, so ... via GotPurpleTree.com and Amazon.com . , According to the Centers ...
(Date:4/17/2019)... ... 17, 2019 , ... Signaled.online is a notification service designed for personal use. ... the web resources and reminder. , The alarm can be useful while traveling abroad, ... you haven’t logged in to the website for several days (this period is set ...
(Date:4/17/2019)... , ... April 17, 2019 , ... ... end-to-end Transaction Tracking and Application Performance Management (APM) for mission-critical applications in the ... recently introduced the latest offering, Nastel XRay® for MQ. , Nastel XRay® for ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... ... April 17, 2019 , ... ... Pennsylvania, Allegheny Health Network (AHN) and Gateway Health have launched a new program ... of life. , AHN’s Enhanced Pain Management Program brings together a range ...
(Date:4/17/2019)... , ... April 17, 2019 , ... The Job ... that will support investigation into the causes of and treatments for Job Syndrome. ... projects that will take place around the globe in three countries, and on three ...
(Date:4/17/2019)... ... April 17, 2019 , ... With the US Food ... to Expedite Development of Oncology Drugs and Biologics’ – it opens ... years of experience helping sponsors manage complex oncology trials, endpoint has ...
Breaking Medicine Technology:
Cached News: